Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
A legfontosabb adatok
- Ki végzi
- Dartmouth-Hitchcock Medical Center
- Hol
- Boston, Burlington és Lebanon (Egyesült Államok)Mind a 4 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 94 fő vett részt
- Kezdés
- 2013. okt. 9.
- Befejezés
- 2025. aug. 25.
- A vizsgálat típusa
- Megfigyeléses
- A regiszteradat frissítve
- 2025. szeptember 15.
- Miért állt le
- Study was administratively closed by IRB
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 7 feltétel megnézéseKevesebb
Egyéb feltételek
- Inclusion/Exclusion Criteria:
- 18 years of age
- Brain tumor(s) to be resected for clinical reasons
- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV
- Adequate tissue available for processing as determined by Pathology
- Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment
- Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy
Helyszínek itt: Egyesült Államok
- Massachusetts General HospitalBoston, Egyesült Államok
- Tufts Medical CenterBoston, Egyesült Államok
- University of VermontBurlington, Egyesült Államok
- Dartmouth Hitchcock Medical CenterLebanon, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas
- A regiszteradat frissítve
- 2025. szeptember 15.